Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation

A. Marzano, A. Marengo, P. Andreone, R. Volpes, D. Canova, C. Cursaro, A. Riili, B. Fiorentino, M. Bacci, S. Guazzini, P. Burra

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aim. The use of hepatitis B immunoglobulin (HBIg) combined with nucleos(t)ide analogues (NUCs) has improved outcomes in post-hepatitis B (PHB) liver transplant (LT), reducing the 1-year recurrence rate below 10%. The aim of this study was to evaluate efficacy and pharmacokinetics of prophylaxis with NUC(s) and intravenous (iv-) or intramuscular (im-) HBIg in 33 PHBLTs, transplanted for more than 1 year. Methods. During the first six months of the study, 18 subjects received 5 000 IU of iv-HBIg every four weeks and 15 patients 2 160 IU/12 mL of im-HBIg every two weeks. In the following six months, 31 subjects were switched to two different concentrations of im-HBIg, 2 160/12 mL (16 patients) or 2 000 IU/6 mL every two weeks (15 patients). Results. All patients remained HBsAg-negative and 30/31 maintained anti-HBs >100 IU/L. Overall mean anti-HBs titer during treatment was 363 IU/mL. Mean HBIg half-life was 21.4, 27.3 and 26 days with intravenous, diluted or concentrated im-preparations, respectively. Conclusion. These results confirm an analogue efficacy and tolerance of iv- and im-HBIg combined with antivirals in prophylaxis of hepatitis B after LT. Anti-HBs titers three times higher than aimed and four weeks mean half-life could suggest the reduction of doses and the elongation of the interval of administration of im-HBIg.

Original languageEnglish
Pages (from-to)373-383
Number of pages11
JournalMinerva Medica
Volume101
Issue number6
Publication statusPublished - Dec 2010

Fingerprint

Hepatitis B
Liver Transplantation
Immunoglobulins
Pharmacokinetics
Half-Life
Transplants
Liver
Hepatitis B Surface Antigens
Antiviral Agents
Recurrence

Keywords

  • Hepatitis B virus
  • Liver transplantation
  • Liver, surgery

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. / Marzano, A.; Marengo, A.; Andreone, P.; Volpes, R.; Canova, D.; Cursaro, C.; Riili, A.; Fiorentino, B.; Bacci, M.; Guazzini, S.; Burra, P.

In: Minerva Medica, Vol. 101, No. 6, 12.2010, p. 373-383.

Research output: Contribution to journalArticle

Marzano, A, Marengo, A, Andreone, P, Volpes, R, Canova, D, Cursaro, C, Riili, A, Fiorentino, B, Bacci, M, Guazzini, S & Burra, P 2010, 'Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation', Minerva Medica, vol. 101, no. 6, pp. 373-383.
Marzano, A. ; Marengo, A. ; Andreone, P. ; Volpes, R. ; Canova, D. ; Cursaro, C. ; Riili, A. ; Fiorentino, B. ; Bacci, M. ; Guazzini, S. ; Burra, P. / Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation. In: Minerva Medica. 2010 ; Vol. 101, No. 6. pp. 373-383.
@article{9ee34c7b3f9144f4af74640b99b6c436,
title = "Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation",
abstract = "Aim. The use of hepatitis B immunoglobulin (HBIg) combined with nucleos(t)ide analogues (NUCs) has improved outcomes in post-hepatitis B (PHB) liver transplant (LT), reducing the 1-year recurrence rate below 10{\%}. The aim of this study was to evaluate efficacy and pharmacokinetics of prophylaxis with NUC(s) and intravenous (iv-) or intramuscular (im-) HBIg in 33 PHBLTs, transplanted for more than 1 year. Methods. During the first six months of the study, 18 subjects received 5 000 IU of iv-HBIg every four weeks and 15 patients 2 160 IU/12 mL of im-HBIg every two weeks. In the following six months, 31 subjects were switched to two different concentrations of im-HBIg, 2 160/12 mL (16 patients) or 2 000 IU/6 mL every two weeks (15 patients). Results. All patients remained HBsAg-negative and 30/31 maintained anti-HBs >100 IU/L. Overall mean anti-HBs titer during treatment was 363 IU/mL. Mean HBIg half-life was 21.4, 27.3 and 26 days with intravenous, diluted or concentrated im-preparations, respectively. Conclusion. These results confirm an analogue efficacy and tolerance of iv- and im-HBIg combined with antivirals in prophylaxis of hepatitis B after LT. Anti-HBs titers three times higher than aimed and four weeks mean half-life could suggest the reduction of doses and the elongation of the interval of administration of im-HBIg.",
keywords = "Hepatitis B virus, Liver transplantation, Liver, surgery",
author = "A. Marzano and A. Marengo and P. Andreone and R. Volpes and D. Canova and C. Cursaro and A. Riili and B. Fiorentino and M. Bacci and S. Guazzini and P. Burra",
year = "2010",
month = "12",
language = "English",
volume = "101",
pages = "373--383",
journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics and efficacy of intravenous or intramuscular hepatitis B immunoglobulins in prophylaxis of hepatitis B after liver transplantation

AU - Marzano, A.

AU - Marengo, A.

AU - Andreone, P.

AU - Volpes, R.

AU - Canova, D.

AU - Cursaro, C.

AU - Riili, A.

AU - Fiorentino, B.

AU - Bacci, M.

AU - Guazzini, S.

AU - Burra, P.

PY - 2010/12

Y1 - 2010/12

N2 - Aim. The use of hepatitis B immunoglobulin (HBIg) combined with nucleos(t)ide analogues (NUCs) has improved outcomes in post-hepatitis B (PHB) liver transplant (LT), reducing the 1-year recurrence rate below 10%. The aim of this study was to evaluate efficacy and pharmacokinetics of prophylaxis with NUC(s) and intravenous (iv-) or intramuscular (im-) HBIg in 33 PHBLTs, transplanted for more than 1 year. Methods. During the first six months of the study, 18 subjects received 5 000 IU of iv-HBIg every four weeks and 15 patients 2 160 IU/12 mL of im-HBIg every two weeks. In the following six months, 31 subjects were switched to two different concentrations of im-HBIg, 2 160/12 mL (16 patients) or 2 000 IU/6 mL every two weeks (15 patients). Results. All patients remained HBsAg-negative and 30/31 maintained anti-HBs >100 IU/L. Overall mean anti-HBs titer during treatment was 363 IU/mL. Mean HBIg half-life was 21.4, 27.3 and 26 days with intravenous, diluted or concentrated im-preparations, respectively. Conclusion. These results confirm an analogue efficacy and tolerance of iv- and im-HBIg combined with antivirals in prophylaxis of hepatitis B after LT. Anti-HBs titers three times higher than aimed and four weeks mean half-life could suggest the reduction of doses and the elongation of the interval of administration of im-HBIg.

AB - Aim. The use of hepatitis B immunoglobulin (HBIg) combined with nucleos(t)ide analogues (NUCs) has improved outcomes in post-hepatitis B (PHB) liver transplant (LT), reducing the 1-year recurrence rate below 10%. The aim of this study was to evaluate efficacy and pharmacokinetics of prophylaxis with NUC(s) and intravenous (iv-) or intramuscular (im-) HBIg in 33 PHBLTs, transplanted for more than 1 year. Methods. During the first six months of the study, 18 subjects received 5 000 IU of iv-HBIg every four weeks and 15 patients 2 160 IU/12 mL of im-HBIg every two weeks. In the following six months, 31 subjects were switched to two different concentrations of im-HBIg, 2 160/12 mL (16 patients) or 2 000 IU/6 mL every two weeks (15 patients). Results. All patients remained HBsAg-negative and 30/31 maintained anti-HBs >100 IU/L. Overall mean anti-HBs titer during treatment was 363 IU/mL. Mean HBIg half-life was 21.4, 27.3 and 26 days with intravenous, diluted or concentrated im-preparations, respectively. Conclusion. These results confirm an analogue efficacy and tolerance of iv- and im-HBIg combined with antivirals in prophylaxis of hepatitis B after LT. Anti-HBs titers three times higher than aimed and four weeks mean half-life could suggest the reduction of doses and the elongation of the interval of administration of im-HBIg.

KW - Hepatitis B virus

KW - Liver transplantation

KW - Liver, surgery

UR - http://www.scopus.com/inward/record.url?scp=79952670217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952670217&partnerID=8YFLogxK

M3 - Article

C2 - 21196896

AN - SCOPUS:79952670217

VL - 101

SP - 373

EP - 383

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 6

ER -